Intercure Ltd. Logo

Intercure Ltd.

Develops and distributes pharmaceutical-grade medical cannabis for patients and pharmacies globally.

INCR | TA

Overview

Corporate Details

ISIN(s):
IL0011063760
LEI:
549300KI5ESXF8F5GP06
Country:
Israel
Address:
11 USSISHKIN STREET, 3844346 HADERA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Intercure Ltd. is a pharmaceutical company focused on the medical cannabis sector. Its operations span research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis-based products. Operating under the brand name Canndoc, the company is recognized as a leading, profitable, and rapidly growing cannabis enterprise outside of North America. Intercure is dedicated to developing and providing high-quality, standardized cannabis products for medical use to patients and pharmacies globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 20:31
Foreign Filer Report
Immediate Report
English 322.0 KB
2025-10-08 20:31
Foreign Filer Report
Immediate Report
English 36.5 KB
2025-09-19 18:49
Foreign Filer Report
Immediate Report
English 473.8 KB
2025-09-19 18:49
Foreign Filer Report
Immediate Report
English 36.5 KB
2025-05-02 16:15
Foreign Filer Report
Form 6-K-InterCure Announces FY2024 Results and Provides Q1 2025 Update:Revenue…
English 203.6 KB
2025-05-02 16:15
Foreign Filer Report
Form 6-K-InterCure Announces FY2024 Results and Provides Q1 2025 Update:Revenue…
English 36.2 KB
2025-05-01 16:08
Foreign Filer Report
FORM 20-F
English 1.9 MB
2025-05-01 16:08
Foreign Filer Report
FORM 20-F
English 36.3 KB
2025-02-13 09:09
Foreign Filer Report
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
English 147.7 KB
2025-02-13 09:09
Foreign Filer Report
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
English 36.3 KB
2025-02-04 00:14
Foreign Filer Report
Results of an Extraordinary General Meeting held on February 3, 2025
English 120.2 KB
2025-02-04 00:14
Foreign Filer Report
Results of an Extraordinary General Meeting held on February 3, 2025
English 36.3 KB
2025-02-02 09:30
Pre-Annual General Meeting Information
A meeting to be held on February 3, 2025-Amendment regarding the private placem…
English 215.3 KB
2025-02-02 09:30
Foreign Filer Report
A meeting to be held on February 3, 2025-Amendment regarding the private placem…
English 36.3 KB
2025-01-28 00:20
Foreign Filer Report
The Extraordinary General Meeting was adjourned to February 3, 2025 due to lack…
English 121.9 KB

Automate Your Workflow. Get a real-time feed of all Intercure Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Intercure Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Intercure Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.